Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia
Web of Science
AuthorHolmes, NE; Robinson, JO; van Hal, SJ; Munckhof, WJ; Athan, E; Korman, TM; Cheng, AC; Turnidge, JD; Johnson, PDR; Howden, BP
Source TitleBMC Infectious Diseases
University of Melbourne Author/sAthan, Eugene; Holmes, Natasha; Howden, Benjamin; Cheng, Allen; Johnson, Paul
AffiliationMicrobiology and Immunology
Medicine and Radiology
Document TypeJournal Article
CitationsHolmes, N. E., Robinson, J. O., van Hal, S. J., Munckhof, W. J., Athan, E., Korman, T. M., Cheng, A. C., Turnidge, J. D., Johnson, P. D. R. & Howden, B. P. (2018). Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. BMC INFECTIOUS DISEASES, 18 (1), https://doi.org/10.1186/s12879-018-3011-2.
Access StatusOpen Access
BACKGROUND: Various studies have identified numerous factors associated with poor clinical outcomes in patients with Staphylococcus aureus bacteraemia (SAB). A new study was created to provide deeper insight into in-hospital complications and risk factors for treatment failure. METHODS: Adult patients hospitalised with Staphylococcus aureus bacteraemia (SAB) were recruited prospectively into a multi-centre cohort. The primary outcome was treatment failure at 30 days (composite of all-cause mortality, persistent bacteraemia, or recurrent bacteraemia), and secondary measures included in-hospital complications and mortality at 6- and 12-months. Data were available for 222 patients recruited from February 2011 to December 2012. RESULTS: Treatment failure at 30-days was recorded in 14.4% of patients (30-day mortality 9.5%). Multivariable analysis predictors of treatment failure included age > 70 years, Pitt bacteraemia score ≥ 2, CRP at onset of SAB > 250 mg/L, and persistent fevers after SAB onset; serum albumin at onset of SAB, receipt of appropriate empiric treatment, recent healthcare attendance, and performing echocardiography were protective. 6-month and 12-month mortality were 19.1% and 24.2% respectively. 45% experienced at least one in-hospital complication, including nephrotoxicity in 19.5%. CONCLUSIONS: This study demonstrates significant improvements in 30-day outcomes in SAB in Australia. However, we have identified important areas to improve outcomes from SAB, particularly reducing renal dysfunction and in-hospital treatment-related complications.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References